Epstein-Barr virus (EBV) infects and transforms resting B lymphocytes in vitro. The virus can also cause B cell lymphomas in immunosuppressed humans. Indeed, EBV-mediated post-transplant lymphoproliferative disease causes significant complications in transplant recipients, including loss of the transplanted organ and even death. The limited treatment options include, nonspecific targeting of B cell surface antigens with monoclonal antibodies or withdrawal of immunosuppression. These therapies fail in ∼50% of patients. Clearly, treatments that specifically target EBV-infected cells are desirable. The EBV antigen EBNA3C regulates cell cycle by targeting critical cellular complexes such as cyclin A/cdk2, SCF Skp2 , and Rb. Here, we use a 20-amino-acid EBNA3C-derived peptide, fused to an HIV TAT tag for efficient delivery, to disrupt cell cycle regulation by EBNA3C. The peptide inhibited hyperproliferation of EBV-infected B cell lines and reduced in vitro immortalization of primary B lymphocytes by EBV. Importantly, the peptide inhibited lymphoblastoid outgrowth from the blood of an EBVpositive transplant patient in vitro.
Tumor viruses have historically provided a starting point for understanding the relationship between molecular disruptions and cancer phenotypes. Indeed, early work with small DNA tumor viruses demonstrated that these viruses drive cell proliferation by targeting and disrupting cell cycle gatekeeper and checkpoint molecules (DeCaprio et al., 1988; Dyson et al., 1989; Whyte et al., 1989) . In the best characterized example, the adenovirus E1A protein, high-risk papillomavirus E7 proteins, and the SV40 large T antigen promote DNA replication by inactivating the retinoblastoma protein (Rb) (DeCaprio et al., 1988; Dyson et al., 1989; Whyte et al., 1989) . The aforementioned viruses are entirely dependent on the host cell's replication machinery to propagate their genomes, and, as such, these viruses likely drive cells into Sphase to better access this machinery. Importantly, cancer only arises when this process becomes deregulated.
Similarly, the activation and proliferation of B lymphocytes are apparently a fundamental part of Epstein-Barr virus (EBV) biology. The prevailing model suggests that EBV utilizes its latency proteins to drive B lymphocyte proliferation, inducing a phenotype that closely mimics antigen-stimulated B lymphocyte activation and expansion (Thorley-Lawson, 2001 ; ThorleyLawson et al., 1982 ThorleyLawson et al., , 1985 . Not surprisingly, EBV has been linked to numerous human lymphoproliferative disorders, including infectious mononucleosis, Burkitt's lymphoma, Hodgkin's disease, and post-transplant lymphoproliferative disease (PTLD) Rickinson and Kieff, 2002) . At present, an open and important question is whether an EBV latency antigen directly targets cell cycle regulatory proteins at the molecular level, as has been described for small DNA tumor virus proteins, or whether EBV relies primarily on transcriptional regulation to modulate the host's normal cell cycle program. The first stories to emerge primarily implicated transcriptional regulation by latency proteins like EBNA2, EBNA-LP, and LMP1 (Arvanitakis et al., 1995; Kempkes et al., 1995; Peng and Lundgren, 1992; Sinclair et al., 1994) . However, more recent studies have begun to suggest a role for EBNA3C in directly binding and regulating critical cell cycle proteins.
Initially, EBNA3C was shown to regulate Rb-directed pathways and to drive cells through the G1/S restriction point (Parker et al., 1996 (Parker et al., , 2000 . More recently, we demonstrated that EBNA3C targets the SCF Skp2 complex thereby regulating the activity and stability of cyclin A/cdk2 and Rb complexes (Knight and Robertson, 2004; Knight et al., 2005a Knight et al., , 2005b . As an extension of this work, we hypothesized that the disruption of EBNA3C-targeted cell cycle pathways might be a viable method for treating EBV-driven cancers. Interestingly, it was recently shown that small EBV peptides can be delivered into cells with high efficiency by tagging the peptides with a basic sequence derived from the HIV transcriptional transactivator (TAT) protein (Farrell et al., 2004) . We therefore generated a TAT-tagged peptide corresponding to a region of EBNA3C critical for cell cycle regulation. We then assessed how this peptide affects both the proliferation of established EBVinfected cell lines and the de novo immortalization of primary B lymphocytes by EBV.
Results
The EBNA3C protein is necessary for EBV-mediated B lymphocyte transformation, although its essential contribution to transformation has remained unresolved (Tomkinson et al., 1993) . Recently we demonstrated that EBNA3C can modulate cell cycle regulatory complexes including cyclin A/cdk2, SCF Skp2 , and Rb (Knight and Robertson, 2004; Knight et al., 2005a Knight et al., , 2005b . These regulatory interactions all map to the amino terminus of EBNA3C, with a 10-amino-acid stretch from residues 140-149 being absolutely essential for regulation of SCF Skp2 and Rb ( Fig. 1A ) (Knight and Robertson, 2004; Knight et al., 2005a Knight et al., , 2005b . Here, we decided to test whether disruption of these interactions, and presumably EBNA3C-driven cell cycle regulation, would impair EBV-mediated B lymphocyte proliferation and transformation. Short basic stretches of amino acids, sometimes referred to as protein transduction domains (PTDs), have been shown to mediate the transport of linked peptides across the plasma membrane into living cells (Denicourt and Dowdy, 2003; Futaki, 2002; Leifert and Whitton, 2003) . Specifically, the PTD of the HIV transcriptional transactivator (TAT) has been used to deliver a 10-amino-acid EBNA2 peptide into EBV-infected B lymphocytes (Farrell et al., 2004) . With the idea that delivery of a short peptide might interfere with EBNA3C-cell cycle interactions thereby inhibiting cell proliferation, we designed an EBNA3C-TAT fusion peptide called E3C-TAT (Fig. 1A) . A 20-amino-acid region of EBNA3C was chosen, amino acids 138-157, which included the aforementioned regions 140-149, and which was predicted by several standard secondary structure prediction protocols to form an alpha helix. An FITC tag was added to the amino terminus to enable the monitoring of peptide delivery, and a scrambled peptide was also designed (SCR) (Fig. 1A ).
EBNA3C-TAT peptides enter cells and localize to both the cytoplasm and nucleus
Previously an EBNA2-TAT peptide was shown to enter cells with a half-maximal uptake of approximately 15 min and a half life of 24 h for the intracellular peptide (Farrell et al., 2004) . The kinetics for our two peptides, E3C-TAT and SCR, were similar (data not shown). A representative image is shown in Fig. 1B , demonstrating peptide in greater than 50% of cells at 24 h when LCLs were treated with 1 μM E3C-TAT. Essentially identical results were obtained for the SCR peptide (data not shown). Further, confocal imaging demonstrated that both peptides were distributed throughout the cytoplasm and nucleus of treated cells (Fig. 1C) .
The E3C-TAT peptide disrupts EBNA3C/Skp2 complexes in vitro
Previously, we demonstrated that the amino terminus of EBNA3C binds the SCF Skp2 complex and utilizes this complex to regulate Rb stability (Knight et al., 2005a (Knight et al., , 2005b . To confirm that the 20-amino-acid peptide derived from EBNA3C indeed competes with full-length EBNA3C for binding to relevant cell cycle molecules, Skp2 was in vitro translated and incubated with a GST-EBNA3C fusion in the presence of increasing concentrations of either E3C-TAT peptide or SCR peptide (Fig. 2) . Indeed, E3C-TAT significantly disrupted Skp2 binding to GST-EBNA3C when compared to SCR control (Fig. 2) . Quantitative analysis of the data indicated that 10 μM E3C-TAT peptide disrupted 80% of Skp2 binding, compared to only 40% with 10 μM SCR peptide. However, it should be noted that at higher concentrations of peptide (i.e., 25 μM), nonspecific competition with the SCR peptide was observed (Fig. 2) .
The E3C-TAT peptide inhibits LCL growth
We predicted that the E3C-TAT peptide would disrupt necessary EBNA3C interactions and inhibit LCL growth when introduced into cells. To test this, we monitored LCL growth over a 96-h period in the presence of varying concentrations of peptide. In the presence of 10% bovine growth serum, 5 and 20 μM E3C-TAT inhibited LCL growth in a dose-responsive fashion (Fig. 3A , left panel). Under conditions of 0.5% serum, the peptide effect was even more potent with 1 μM E3C-TAT significantly inhibiting growth at 96 h (Fig. 3A, right panel) . To confirm the specificity of this effect, the SCR peptide was introduced into two independently prepared LCLs alongside E3C-TAT, both at 20 μM levels. Again 20 μM E3C-TAT significantly inhibited LCL growth while 20 μM SCR was indistinguishable from the no-peptide control (Fig. 3B) .
In addition to monitoring LCL proliferation with the aforementioned growth curve assay, we also measured proliferation using PKH26, a membrane-staining dye. As cells divide, the dye is diluted in the plasma membrane resulting in reduced fluorescence intensity which can be monitored by FACS. Two independently prepared LCLs were stained with PKH26 and then maintained in dye-free medium for 72 h. The medium also contained 10% serum and either E3C-TAT peptide or SCR control as indicated (Fig. 3C) . In LCLs treated with no-peptide or SCR control, approximately 80% of cells demonstrated reduced fluorescence intensity and were consequently judged to have proliferated over the 72-h course of the assay (Fig. 3C) . In contrast, only 40% of E3C-TAT-treated cells showed reduced fluorescence intensity (Fig. 3C ). These PKH26 data are consistent with the above growth curves demonstrating decreased LCL proliferation in the presence of the E3C-TAT peptide.
The E3C-TAT peptide specifically inhibits EBV-infected cells and EBV-mediated transformation
We next asked whether other B cell lines not infected with EBV would be similarly inhibited by the E3C-TAT peptide. To this end, BJAB, DG75, and Loukes were compared alongside an LCL in a 96-h growth curve experiment. While the LCL again showed significant growth inhibition in the presence of 20 μM E3C-TAT peptide, BJAB, DG75, and Loukes treated with E3C-TAT were statistically indistinguishable from no-peptide controls (Fig. 4A) .
To further explore the EBV dependence of E3C-TAT inhibition, we asked whether E3C-TAT peptide could inhibit the transformation of primary B cells by EBV in vitro. Primary B lymphocytes were prepared from donor blood as described in Methods (Robertson and Kieff, 1995) . Lymphocytes were mixed with viral supernatant and seeded into 96-well plates. 24 wells were treated with no-peptide, 24 with 20 μM E3C-TAT peptide, and 24 with 20 μM SCR peptide. Wells were fed every 3 days with fresh medium supplemented with 20 μM peptide. At 6 weeks, wells were scored for obvious LCL outgrowth by blinded observers. For the no-peptide control and the SCRtreated cells, 10 and 11 wells or close to 50% of the wells, respectively, showed signs of obvious LCL-like outgrowth with multiple robust foci in each of the wells (Fig. 4B) . In contrast, for E3C-TAT-treated cells only 4 wells showed LCL-like outgrowth, with fewer foci that did not continue outgrowth over 2-3 months (Fig. 4B) .
The E3C-TAT peptide inhibits the outgrowth of EBV-positive lymphoma cells isolated from a PTLD patient
The patient described in Fig. 5 has a history of kidney transplant for polycystic kidney disease. She developed a B cell, EBV-positive PTLD 2.5 years ago. At that time, she was treated with reduction in immunosuppression and rituximab (trade name Rituxan, an anti-CD20 monoclonal antibody) and had a complete response. One year later, she developed a new adenopathy and her EBV PCR (which had been negative for a year) was again positive. Two preliminary needle biopsies showed T cells only (no evidence of her old PTLD). However, she finally had an open biopsy which showed EBV-positive Hodgkin's disease.
As this patient was in an immunosuppressed state and had a clear EBV-driven proliferative process, we decided to test whether the E3C-TAT peptide would prevent spontaneous EBV-mediated lymphocyte outgrowth from this patient. Total PBMCs were isolated from patient blood as described in Methods and seeded into 24-well plates in the presence of either E3C-TAT or SCR peptide. Importantly, no exogenously prepared virus was added and no effort was made to either extract or inhibit T cells as in the aforementioned transformation experiments. At 4 weeks, wells were scored for obvious LCLlike outgrowth by blinded observers.
E3C-TAT significantly inhibited LCL-like outgrowth (Fig.  5A) . While 18 and 19 out of 24 wells were scored positive for no-peptide control and SCR, respectively, only 6 wells were scored positive for the E3C-TAT sample after 4 weeks (Fig. 5A) . Representative LCL-like outgrowths from SCR-treated cells are shown in Fig. 5B . FACS analysis confirmed that these cells are CD19-positive (Fig. 5C) , and, importantly, three independent patient-derived LCLs tested by Western blotting were EBNA3C-positive, confirming the presence of EBV in the proliferating lymphoblastoid cell lines (Fig. 5D ).
Discussion
It is now widely recognized that EBV plays a causative role in lymproliferative disease of patients receiving sustained immunosuppression (Nalesnik, 1998) . Post-transplant lymphoproliferative disease (PTLD) is seen in 1% to 2% of renal and liver transplant patients ). The incidence is even higher in heart and lung transplant recipients (3% to 8%) where T cell suppression is more dramatic . The EBV dependence of these tumors is underscored by immunostaining which invariably demonstrates lesions with EBNA1, EBNA2, and LMP1-positive cells, consistent with the formation of LCL-like outgrowths in the absence of cytotoxic T lymphocyte surveillance (Liebowitz, 1998; Thomas et al., 1990; Young et al., 1989) . Patients who develop PTLD are generally managed by reducing the doses of immunosuppressive drugs which will result in regression of PTLD in approximately half of patients. Unfortunately, the potential for allograft rejection prohibits this approach in many patients. An alternative treatment is the CD20 monoclonal antibody rituximab which can be employed alone or in combination with chemotherapy. Rituximab has variable effectiveness in patients with follicular B cell non-Hodgkin lymphoma (Macsween and Crawford, 2003) .
EBNA3C is essential for EBV-mediated B lymphocyte transformation, and presumably proliferation (Tomkinson et al., 1993) . While there is no consensus as to the mechanism by which EBNA3C contributes to transformation, recent evidence has clearly implicated EBNA3C in regulation of the cell cycle. EBNA3C promotes the G1/S transition and targets the SCF complex to regulate cyclin A/cdk2 and Rb (Knight and Robertson, 2004; Knight et al., 2005a Knight et al., , 2005b Parker et al., 1996 Parker et al., , 2000 . In this study, we tested whether a small EBNA3C peptide, with the potential to block the interaction between fulllength EBNA3C and cell cycle regulators, might limit LCL proliferation and abrogate the transformation of B lymphocytes by EBV.
For this study, amino acids 138-157 of EBNA3C were chosen; these include the critical regions 140-149 and are predicted by several standard secondary structure prediction protocols to form an alpha helix. These amino acids were fused to a carboxy-terminal HIV TAT which had previously been used to deliver a smaller EBNA2-derived peptide into LCLs (Farrell et al., 2004) . Indeed, the EBNA3C peptide E3C-TAT was efficiently delivered into cells and, importantly, specifically inhibited the proliferation of previously established EBVinfected cell lines. This was in contrast to control experiments with a scrambled version of the E3C-TAT peptide which showed no inhibition of proliferation. In another important control, the E3C-TAT peptide did not inhibit the proliferation of lymphocyte cell lines which were not infected with EBV. These data were made more relevant by the ability of the peptide to inhibit the efficiency of viral transformation of purified primary B lymphocytes. Finally, the peptide also blocked the spontaneous emergence and outgrowth of EBV-transformed cells when PBMCs were isolated from the blood of an EBV-positive, immunosuppresed, kidney transplant recipient.
Certainly, further studies are needed to better understand which of the functions of EBNA3C is specifically disrupted by the devised peptide. Also, given the known toxicity of the TAT peptide, additional mechanisms may be desirable for the delivery of EBNA3C inhibitory molecules into cells, including the identification of small molecule inhibitors that are capable of specifically inhibiting the aforementioned interactions. Nevertheless, we find the experiments presented here to be particularly promising as they relate to the potential role of EBNA3C-targeting therapeutics in the treatment of EBNA3C-positive B cell cancers.
Methods

Peptide synthesis
Peptides were purchased from Alpha Diagnostic International (San Antonio, Texas). E3C-TAT had a sequence of Fitc-TQHILCFVMAARQRLQDIRRYGRKKRRQRRR with an average mass of 4356 daltons. SCR had a sequence of Fitc-IQRTCQRQAIDLRHVRAMFLYGRKKRRQRRR. Purity of the peptide preparations was confirmed by HPLC and peptide identity was confirmed by MS. The 11-amino-acid HIV TAT tag has been previously described (Farrell et al., 2004) .
GST pull-down assays
GST fusion proteins were purified from bulk E. coli cultures following induction with IPTG as described previously (Knight et al., 2005b) . For in vitro binding experiments, GST fusion proteins were incubated with 35 S-labeled, in vitro 
Growth assays
For growth curves, 50,000 cells were seeded into 100 μl RPMI 1640 (Invitrogen Corporation, Carlsbad, California). RPMI was supplemented with the indicated concentrations of bovine growth serum and either E3C-TAT or SCR peptide. Cultures were fed every 24 h with 100 μl fresh medium supplemented with peptide. Total cells were counted with a hemocytometer at 48 and 96 h.
The optimal concentration of PKH26 (Sigma, St. Louis, Missouri) for staining and viability of LCLs was determined to be 4 μM. Staining of cells was per the manufacturer's recommendation. Briefly, 5 × 10 6 cells were pelleted, washed with medium without serum, and resuspended in 0.5 ml of diluent, ensuring a single cell suspension by pipetting gently. Equal volume of PKH26 (8 μM) was added to the single cell suspension. The cells were incubated at room temperature for 5 min and the reaction was stopped by adding 1 ml of ice-cold bovine growth serum. The cells were washed 3 times with ice cold complete medium, to get rid of any free dye. Immediately following staining with PKH26, staining was analyzed using a FACScan flow cytometer (BD Biosciences, San Jose, California). The remaining cells were divided into samples of 500,000 cells and seeded into 1 ml RPMI 1640. Media were supplemented with 10% bovine growth serum and either no-peptide (control) or one of E3C-TAT or SCR peptides. Cultures were fed every 24 h with 1 ml fresh medium supplemented with peptide. The samples were assayed 72 h post-seeding using a FACScan flow cytometer.
B cell transformation assays B95.8 virus was prepared from fresh LCLs by seeding 10 million cells into 10 ml RPMI plus 10% bovine growth serum. Lytic replication was induced by treating cultures with TPA and butyrate for 6 days. Culture supernatant was harvested and mixed with clarified cell extracts prepared by freeze/thaw of the cell pellet. The pooled viral supernatant was passed through a 0.45-μm filter.
Primary B lymphocytes were prepared from donor blood. Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll gradient, and T cells were removed by rosetting with sheep red blood cells according to standard protocol (Robertson and Kieff, 1995) . Primary B lymphocytes were mixed with viral supernatant and seeded into 96-well plates with 100,000 cells, 50 μl viral supernatant, and 20 μM peptide per well. Wells were fed every three days with 50 μl fresh RPMI plus 10% bovine growth serum, supplemented with 20 μM peptide. At 6 weeks, wells were scored for obvious LCL outgrowth by blinded observers.
Patient samples
Total PBMCs were isolated from patient blood by Ficoll gradient and seeded into 96-well plates with 50,000 PBMCs, 50 μl RPMI plus 10% bovine growth serum, and 20 μM peptide per well. Wells were fed every 3 days with 50 μl fresh RPMI plus 10% bovine growth serum, supplemented with 20 μM peptide. At 4 weeks, wells were scored for obvious LCL outgrowth.
Flow cytometry
× 10
5 cells were blocked with Fc block (BD Biosciences, San Jose, California) for 15 min and then stained with Allophycocyanin (APC)-anti-human CD19 (1:200 dilution, BD Biosciences) and appropriate isotype control antibody (1:200 dilution, BD Biosciences) for 30 min at 4°C. Cells were collected, washed and acquired with a FACSCalibur flow cytometer (BD Biosciences) and data were analyzed with FlowJo software (Tree Star, Inc., Ashland, Oregon).
